Borna disease virus-specific T cells protect against or cause immunopathological Borna disease by unknown
Borna  Disease  Virus-specific  T  Cells  Protect  Against 
or Cause  Immunopathological  Borna  Disease 
By J. A.  Richt,* A.  Schmeel,* K.  Frese,~ K.  M.  Carbone,~ 
O. Narayan$, and R.  Rott* 
From the  "lnstitut f~r  Virologie; the Ilnstitut far  Veteriniir-Pathologie, D-35392 Giessen, 
Germany; and the SThe Johns Hopkins  University, School of Medicine, Baltimore, Maryland 
212O5 
SuInnlsry 
In this report we show that passive immunization of Lewis rats with viable CD4 +, Borna disease 
virus (BDV)-specific T cells before infection with BDV resulted in protection against BD, whereas 
inoculation of these T  cells after BDV infection induced clinical disease with more rapid onset 
than seen in BDV control animals. The protective as well as encephalitogenic effector functions 
of BDV-specific CD4 § T ceils were mediated only by viable BDV-specific T ceils. The protective 
situation was obtained by passive transfer of BDV-specific T  cells into animals inoculated later 
with virus, whereas the immunopathological situation was observed when virus-specific T cells 
developed normally or after adoptive transfer, and appeared on the scene after considerable virus 
replication in the brain. 
B 
orna  disease  virus  (BDV) 1 is  an  unclassified  single-, 
negative-stranded RNA virus (1, 2) that causes enceph- 
alopathy in nature preferentially in horses and sheep. Promi- 
nent clinical  signs include excitation, ataxia,  abnormal be- 
havior,  paresis, and paralysis, often leading to death (3, 4). 
The histopathological lesions consist of a disseminated menin- 
goencephalitis with perivascular infiltrates and pathognomonic 
intranuclear "Joest-Degen" inclusion bodies in neurons and 
astrocytes (3-5). Experimentally, BDV causes a persistent in- 
fection in the central nervous system (CNS) in a wide range 
of animal species, ranging from chickens to nonhuman pri- 
mates.  In adult animals infection is restricted to the CNS 
(4-6). The presence of BDV-specific antibodies in psychiatric 
patients indicates  that BDV might be a possible hazard for 
man (7). 
Studies  on pathogenesis of BDV infection in Lewis rats 
have shown that the disease is mediated by a virus-induced 
immunopathological reaction.  Neurological disorders  and 
inflammation in the CNS did not occur in immunoincompe- 
tent animals, such as newborn or athymic-infected rats or 
rats immunosuppressed by cyclophosphamide or Cyclosporin 
A in spite of persistent virus replication in the CNS (6, 8-10). 
The effect of drug-induced immunosuppression,  however, was 
overcome by adoptive transfer of cells from the spleen-  or 
from lymph nodes of acutely infected, syngeneic rats.  The 
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same effect was achieved by injection of syngeneic, BDV an- 
tigen-specific CD4 + T  lymphocytes (NM  1),  which had 
been established in vitro. These BDV-specific NM 1 T cells 
were able to induce acute Borna disease (BD) and cause se- 
vere  meningoencephalomyelitis in  cyclophosphamide im- 
munosuppressed  BDV-infected virus  carriers;  this  T  cell 
transfer did not have any effect in noninfected recipients (11, 
12). Furthermore, the BDV-specific  T  cell line was able to 
destroy persistently BDV-infected astrocytes in conventional 
cytotoxicity assays (13). These findings highlight the pivotal 
role of CD4 + T  cells in the pathogenesis of BD  (11, 12). 
In the present study we describe  that passive transfer of 
CD4 +, BDV-specific T  cells into naive syngeneic recipient 
rats before virus infection conferred a protective immunity 
against an otherwise fatal virus-induced immunopatholog- 
ical disease of the CNS whereas transfer of these cells begin- 
ning on day + 3 after intracerebral infection with virus and 
up to 10 d thereafter resulted in accelerated onset of BD. Thus, 
treatment of virus-specific  CD4 § T  cells can either induce 
or prevent clinical BD in BDV infected rats, depending on 
the time of transfer. 
Materials and Methods 
BDV and BDV Antigens.  BDV stock was prepared from BDV- 
infected rat brain as 10% homogenates in Glasgow Minimal Es- 
sential Medium (GMEM) containing 2% FCS as previously de- 
scribed (14). BDV strain 5/25/92 was used throughout these studies. 
BDV antigens were purified  from BDV-infected  rat brains by affinity 
chromatography  using monoclonal  and polyclonal  antibodies against 
BDV (12, 15). 
Infection and Immunosuppression.  4-wk-old  Lewis rats were in- 
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diluted 1:10 in GMEM/2% FCS. Controls were mock infected in- 
tracerebrally with dilution medium only. Immunosuppression was 
started I d after virus inoculation by a single intraperitoneal injec- 
tion of 150 mg/kg cyclophosphamide (Endoxan; Asta  Pharma, 
Frankfurt, Germany) (6). 
Infectivity Assay and Antigen Detection.  Virus infectivity was de- 
termined in BDV susceptible rabbit embryo brain cells by an indirect 
immunofluorescence assay (IFA) with a rat anti-BDV immune serum 
(14). BDV-specific proteins were detected by immunoblotting using 
polyclonal rat and monoclonal mouse antibodies specific for BDV 
(15,  16). 
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Anal- 
ys/s.  RNA was reverse transcribed using BDV-specific  primers (1024 
specific) and subsequently amplified by the PCR technique as de- 
scribed recently (17). RNA was extracted from brain tissues (frontal 
cortex) using the acid guanidinium thiocyanate-phenol-chloroform 
method (18). 
T CellLines.  A purified protein derivative of Mycobacterium tuber- 
culosis (PPD)-specific CD4 + T  cell line,  derived from Lewis rats, 
was kindly provided by Dr. R. Gold (Neurologische Universit~its- 
klinik  W~irzburg,  Germany). The BDV-specific CD4 § T  cells, 
NM 1 (11, 12) and AS (Schmeel, A., and J. A. Richt, unpublished 
results), had been developed by immunization of Lewis rats with 
BDV antigen as described previously (11, 12). Briefly, aduh Lewis 
rats were immunized with purified BDV-specific antigen in com- 
plete Freund's adjuvant into their hind footpads. The regional lymph 
nodes were homogenized and the bulk cultures stimulated with 
BDV antigen. The CD4 + T  cell lines were maintained by alter- 
nating cycles of stimulation with antigen in the presence of irradi- 
ated, syngeneic APC for 3 d followed by expansion in II.-2 con- 
taining medium for 7-10 d. All media were based on RPMI 1640 
(Gibco, Eggenstein,  Germany). 
Adoptive Transfer of T Cells.  Naive normal rats (3 wk old) re- 
ceived BDV-specific (NM 1 or AS) or PPD-specific  (PPD T cells) 
CD4 + T cells, resuspended  in 0.5-t.0 ml Hepes-buffered medium, 
by intravenous injection of 1-3  x  106 T cells on day 20 and day 
5 before intracerebral infection with BDV (day 0). Transfer of these 
CD4 § T  cells on days 5 and 20 before infection with BDV was 
chosen to have a considerable time lag between transfer and infec- 
tion so that a sufficient number ofeffector T cells had a good chance 
for appropriate homing. The adoptive transfer on days +3 and  +10 
into untreated or cyclophosphamide treated, BDV-infected rats was 
done with 2.5  x  106 activated BDV-specific (NM  1 or AS) or 
PPD-specific T cells. In some experiments,  the CD4 § T cells were 
inactivated either by two cycles of freezing and thawing or by in- 
cubation under UV light at room temperature overnight or irradi- 
ation with 6,000 tad before intravenous injection. 
Histopathology.  Brains were fixed in 4% formalin and embedded 
in paraffin. Sequential sections were stained with hematoxylin and 
eosin or with antibodies either specific for the 38/39-kD BDV an- 
tigen (routine monoclonal antibody Bo-18; reference 15) or for the 
astrocyte-specific  glial fibrillary acidic protein (anti-GFAP) (poly- 
clonal rabbit antibody; Dako, Hamburg, Germany). Specific reac- 
tions were detected with the biotin-avidin-peroxidase system (Vec- 
tastain ABC;  Vector;  Camon,  Wiesbaden, Germany). 
Results and Discussion 
Adoptive Transfer of Live and Inactivated NM 1 T Cells before 
BDV-infection.  Control BDV-infected rats developed signs 
of BD and significant weight loss after day 24 (_+2) post in- 
fection (p.i.).  The humoral  immune response  to BDV an- 
tigens in these BDV-infected animals  started at day 17 p.i. 
(IFA titer 1:40), reached maximal titers on day 30 p.i. (IFA 
titer 1:5,120) and was present throughout the entire observa- 
tion period of 68 d. 10 normal 4-wk-old Lewis rats were in- 
jected intravenously twice (on days  -20 and  -5) with 1-3 
x  106 viable BDV-specific NM  1  T  cells  and  challenged 
later (day 0) by intracerebral inoculation with BDV. None 
of these animals developed BD during an observation period 
of more than 1 yr (Table 1). The protective effect of this treat- 
ment was also reflected by the body weight of these animals. 
Rats treated with viable NM  1 T  cells had similar growth 
rates as uninfected, untreated controls and in addition showed 
normal mating behavior and produced normal litters (data 
not  shown).  Antibodies  to BDV-specific antigens  in these 
animals protected by NM 1 T  cell treatment became detect- 
able 6 d post challenge. The antibody titers in these protected 
animals after 24 days p.i. were of a similar magnitude as those 
that developed in BDV-infected control rats. This indicated 
that the CD4 + BDV-specific T  cell line NM  1 provided ad- 
ditional specific help for the generation of antibodies by BDV- 
specific B  lymphocytes  in  vivo.  Passive  transfer of CD4 + 
control T  cells (PPD T  cells) or transfer of inactivated NM 
1 T  cells before BDV challenge resulted in onset of clinical 
BD, significant weight loss and production of BDV-specific 
antibodies similar as observed in BDV infected control animals 
(Table 1). Comparable results were obtained when analogous 
experiments were carried out with a more virulent BDV strain 
(strain P2/89), which causes disease of more rapid onset, or 
another CD4 +, MHC class H-restricted BDV-specific T  cell 
Table  1.  Adoptive Transfer of CD4 § T  Cells before Infection 
with BDV 
No. 
Treatment  of animals  Clinical BD  Encephalomyelitis 
Viable  NM  1 
T  cells 
Inactivated 
NM  1 T  cells 
10  0/10  10/10 
3*  3/3  3/3 
3*  3/3  3/3 
4s  4/4  4/4 
Viable  PPD 
T  cells  4  4/4  4/4 
BDV controls  9  9/9  9/9 
* NM 1 T cells were inactivated by two rounds of freezing/thawing be- 
fore intravenous injection. 
r NM 1 T cells were inactivated with UV light before intravenous in- 
oculation. 
S NM  1 T cells were inactivated by irradiation with 6,000 rad before 
intravenous injection. 
CD4 + BDV-specific  NM 1 T cells were transferred after restimulation 
with BDV-specific  antigen and APCs on days 20 and 5 before BDV in- 
fection. As a control, PPD-specific T cells were used. 
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in vivo and in vitro functions as described for the BDV-specific 
NM  1 T  cells  (11,  12). 
Brain homogenates from T  cell-treated animals were ana- 
lyzed for infectivity, viral antigen,  and the presence of viral 
RNA at various times after virus inoculation. As shown in 
Table 2, rats treated with viable NM  1 T  ceils followed by 
inoculation  with  BDV became infected although  they did 
not  become  ill.  Infectious  virus  (~<10  e  TCIDs0/ml)  was 
found in brains of these animals between day 9  and day 15 
p.i. However, beyond day 15 p.i., infectious virus could not 
be detected by conventional infectivity assays employing rabbit 
embryo brain cells (reference 14; Table 2). Similar lack of evi- 
dence for infection was obtained when brain  homogenates 
from T  cell-treated, protected animals were analyzed for BDV 
RNA  by  RT-PCR  using  BDV  p24-specific primers  (17). 
Using this procedure, we detected viral R,  NA between day 
9  and  15 p.i.,  but  no longer beyond day  15  p.i.  (data  not 
shown). Similar results were obtained when brain homogenates 
were analyzed for the presence of viral antigens in Western 
blots. Here again, at early time points p.i. (days + 9 and  + 12 
p.i.),  BDV  antigens  were present in brain  sections of NM 
1 T  cell-treated, protected animals. However, beyond day 15 
p.i., BDV-specific antigens were no longer detectable in the 
T  cell-treated, protected group (data not shown). Immuno- 
histohistological staining of brains from NM 1-treated, pro- 
tected animals  for the presence of BDV antigen confirmed 
the results  obtained by immunoblotting.  Here again,  only 
few BDV-specific antigen-expressing cells were detectable in 
the brain  of these animals  at early time points  (days 9-15 
p.i.) and no BDV-specific staining could be observed at any 
later time point (beyond day 15 p.i.; Fig.  1 b). The localiza- 
tion of BDV antigen in the NM 1-treated, protected animals 
was  never disseminated;  antigen was  detected only within 
neurons of the hippocampus and frontal cortex. In contrast, 
BDV infected controls or animals adoptively transferred with 
inactivated BDV-specific or control CD4 + T  cells followed 
by virus inoculation developed typical persistent infection and 
disease.  In the latter animals,  virus titers started to rise en 
day 9  p.i.,  reaching a plateau  of maximal  infectivity levels 
on day 27 p.i.  which was maintained  (__.  1 log) during the 
entire observation period of 68 d  (Table 2).  BDV-infected 
control animals had high levels  of BDV antigens and BDV 
RNA as tested by Western blot analysis or RT-PCR  at all 
time points  beyond day 9  p.i.  (data  not  shown). 
Brain sections of protected animals treated twice with viable 
BDV-specific T  cells before infection had a severe inflamma- 
tory response predominantly in the hippocampal area of the 
CNS and a less prominent reaction in the frontal cortex. This 
inflammatory reaction started on day 9 p.i.  (Table 2). Mas- 
sive mononuclear perivascular and parenchymal infiltrations 
were prominent in the CA3-area of the hippocampus.  It is 
interesting to note that many plasma cells were already present 
at this early stage of infection (day 9 p.i.), a finding that coin- 
cided with detectable anti-BDV antibodies. Examination of 
brain sections from protected animals on day 21 p.i. showed 
massive encephalitis and astrogliosis (Fig. 1, a and c) which 
had started earlier than in control animals (Fig.  1, d and J). 
Table  2.  Summary of Prominent Histopathological Findings and Presence of Antigen and Infectious Virus in the Cerebral Tissue of 
Protected Rats and Control Animals 
Histopathology 
Virus infectivity 
Encephalitis*  Astrogliosis*  BDV antigens  (TCIDs0) II 
Days p.i.  Control  Protected  Control  Protected  Control  Protected  Control  Protected 
per mt 
3  ......  <lOt  <101 
6  ......  <101  <101 
9  -  +  -  +  +  +  101  102 
12  -  + +  -  +  +  +  +  10~  10~ 
15  -+  +  +  -  + +  +  +  + +  +  103  ~<101 
21  + +  +  +  +  +  +  +  + +  + +  +  -  105  <(101 
27  +  +  +  +  +  +  +  + +  + +  +  -  106  ~101 
68  +  -  +  +  +  +  +  +  -  10s  <10~ 
" Encephalitis: + Very few small perivascular infiltrates. + Few perivascular  and parenchymal infiltrates. + + Few perivascular and more prominent 
parenchymal infiltrates.  + + +  Multiple perivascular and massive parenchymal infiltrates. 
Astrogliosis:  +  Few.  + +  Moderate.  + + +  Large numbers of hypertrophic GFAP-reactive astrocytes in lesions. 
S BDV-antigen: -  BDV-antigen not demonstrable. +  Few immunoreactive  neurons (in frontal cortex and hippocampus). + +  Multiple immunoreac- 
tion of neurons (in frontal cortex and hippocampus). + + +  Massive disseminated immunoreaction of neurons and neuropil. 
II Virus infectivity:  Infectivity assays were performed on fetal rabbit brain cells inoculated with the respective  virus dilutions as described  previously  (14). 
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was still prominent, whereas infiltration in the frontal cortex 
was rather sparse (Table 2). Inflammation in the brain of NM 
1-treated animals began to recede on day 30 p.i., in contrast 
to maintenance and/or further progression of lesions in the 
controls (Table 2).  Only sparse inflammatory reaction was 
found at later time points in the CNS ofNM 1 T cell-treated, 
BDV infected rats. Similar results were reported when the 
F1 generation of Black Hooded X  Lewis rats were infected 
with BDV. In this case, no clinical  disease was noticed in 
spite  of cellular infiltrates in the cerebral  tissue (19). 
In control BDV infected rats, which developed fulminant 
disease, the time of appearance of inflammatory infiltrates in 
the brain did not begin until after day 15 (in contrast to day 
9 in NM 1 treated, protected animals; see Table 2). At day 
15 p.i. sparse perivascular  infiltration in the hippocampus of 
control BDV infected rats was noticed. BDV antigen staining 
was found as early as day 9 and had become disseminated 
throughout the brain by day 15 p.i. At day 21 p.i. moderate 
perivascular and parenchymal infiltrates were seen, especially 
in the frontal cortex and hippocampus (Fig.  1 d and Table 
2).  At this time, only mild astrogliosis was apparent (Fig. 
l f). Similar infiltrations and BDV antigen dissemination as 
described for day 21 were found on days 27 and 30 p.i.  in 
the brain of control BDV-infected rats (Table 2). Besides par- 
ticipation of mononuclear ceils in the inflammatory reaction 
a moderate astrogliosis became visible, especially in the hip- 
pocampus. Animals sacrificed 68 days p.i. still had dissemi- 
nated patches of BDV antigen and a strong astrogliosis (Table 
2). However, the inflammatory reaction in the CNS receded 
and only sparse parenchymal infiltrates of mononuclear cells 
were discernible in the cerebral  tissue (Table 2).  Treatment 
of naive rats with inactivated BDV-specific CD4 + T cells or 
control PPD T cells and subsequent infection resulted in similar 
histological alterations described for  the untreated BDV- 
infected controls. 
Adoptive  Transfer of Live and Inactivated NM I  T Cells after 
Infection with BDV.  In earlier reports we had shown that 
activated CD4 §  NM  1 T  cells were able  to induce acute 
clinical disease and severe meningoencephalomyelitis when 
transferred into rats (on day + 10) that had been inoculated 
with BDV (day 0) and treated with cyclophosphamide (day 
+1)  (11, 12). To determine the time limit for a successful 
protective transfer of CD4 + BDV-specific NM 1 T cells, we 
conducted adoptive transfer experiments on days + 3 and + 10 
after BDV infection. Recipient rats were either left untreated 
or they were treated with cyclosphosphamide (150 mg/ml) 
i d after BDV infection. When activated NM 1 T cells were 
transferred on days +3 or + 10 p.i., clinical BD was observed 
between days 10 and 15 p.i., several days before disease had 
developed in control BDV-infected animals (day 24 p.i.; Table 
3). The incubation period between transfer and onset of BD 
therefore varied from 4 to 9 d, indicating that dissemination 
of viral antigen and the presence of an adequate number of 
effector T cells in the CNS determined the onset of BD (Tables 
2 and 3; and Fig. 1, g-i).  NM 1 T cells, inactivated by x-ray 
irradiation or freezing and thawing treatment, were not able 
to induce clinical BD, proving that only viable T  cells had 
encephalitogenic effector functions (Table 3). 
In this report we have shown that passive immunization 
of Lewis rats with viable CD4 +, BDV-specific  T  cells be- 
fore challenge with BDV resulted in protection against BD 
with an ensuing period of transient virus replication and en- 
cephalitis. In contrast, inoculation of these T cells after BDV- 
infection induced clinical disease with a more rapid onset than 
seen in BDV infected control animals. The protective as well 
as encephalitogenic  effector functions of BDV-specific CD4 + 
T  cells were mediated only by viable BDV-specific  T  cells. 
The mechanism of inhibition of  virus spread by BDV-specific 
T cells could be explained by the action of antiviral cytokines, 
e.g., interferon-')', tumor necrosis factor ot or nitric oxide at 
the site of viral replication (20, 21). The immediate presence 
of a relatively high number of BDV responsive T cells would 
ensure a maximal release of cytokines upon contact with the 
first BDV antigens produced and subsequent targetting of 
other immune cells to this site; this would impair further 
virus replication. In contrast, the response of these CD4 + 
T cells, when administered at time points when viral antigen 
had disseminated throughout the CNS had no longer the 
quality of a virostatic effect.  The cells rather were respon- 
sible for the adverse consequence of promoting the encepha- 
litis, possibly with concomitant lysis of infected neurons and 
glia cells. There was no definite evidence for a cytolytic  effect 
of T  cells,  however,  since  no unequivocal degradation of 
neurons or glial cell was manifest in the cerebral  tissue of 
these NM 1 T cell-treated animals at this stage of infection. 
With the methods available and under the experimental con- 
ditions employed, it cannot be decided, therefore, whether 
lysis of such cells by the NM 1 T cells (13) or BDV-specific 
CD8 +  T  cells  (22)  would represent  the  decisive  step  in 
pathogenesis. 
Results of this study contrast clearly with data obtained 
Figure 1.  Brain  sections from different  groups of BDV infected  rats. (a-c) BDV infected  rat, injected  with viable NM 1 T cells 20 and 5 d before 
infection, sacrificed  21 d p.i. (a) Massive  perivascular and parenchymal  mononuclear  infiltrations  in the hippocampus. (b) Subsequent slides with total 
lack of BDV antigen and (c) Prominent astrocytic  hypertrophy.  (d-J) BDV infected  control rat, 21 d p.i. (d) Moderate perivascular and parenchymal 
mononuclear  infiltration  in the hippocampus.  (e) Subsequent  slide  exhibiting  massive  BDV antigen  reaction  in neurons  and neuropil. Lack  of  immunoreaction 
in perivascular inflammatory  cells and molecular  layer. (f) Slide from the same hippocampal area with moderate astrocytic  hypertrophy.  (g-i) BDV 
infected  rat after  immunosuppression  on day 1 p.i. and passive transfer  with 2.5 x 106 activated  BDV-specific  NM 1 T cells on day 10 p.i. and sacrificed 
14 days  p.i. (g) Moderate  perivascular  and parenchymal  mononuclear  infiltration  in the hippocampus. (h) Slide  from  the same hippocampal  area exhibiting 
massive BDV immunoreaction.  Only few positive neurons in the pyramidal  layer and weak reaction in the molecular  layer. (i) Slide from the same 
hippocampal area with moderate astrocytic  hypertrophy.  (a, d, and g) Hematoxylin  and eosin. (b, e, and h) ABC-stain for BDV antigen with mAb 
Bo 18 counterstained  with hematoxylin.  (c, f  and i) ABC-stain for GFAP, counterstained  with hematoxylin.  Magnification ￿  100. 
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Transfer  Onset of BD 
Group  CY*  days p.i.  days p.i.  Encephalitis 
BDV  No  No  24  -+  2  8/8 
BDV  +  NM  1 
T  cells*  No  3  10  _+  2  3/3 
BDV  +  NM  1 
T  cells*  No  10  14  _+  1  2/2 
BDV  Yes  No  No disease  0/8 
BDV  +  NM  1 
T  cells*  Yes  3  12  -+  2  4/4 
BDV  +  NM  1 
T  cellsr  Yes  10  14  _+  1  10/10 
BDV  +  NM  1 
T  cells,  inactivatedS  Yes  3  No disease  0/3 
BDV  +  NM  1 
T  cells,  inactivatedS  Yes  10  No disease  0/4 
BDV  +  PPD 
T  cellsll  Yes  3  No disease  0/3 
BDV  +  PPD 
T  cells  il  Yes  10  No disease  0/4 
* cY  =  cyclophosphamide (150 mg/kg). 
* Animals were inoculated intravenously with 2.5  ￿  106 activated BDV-specific NM 1 T cells. 
S NM 1 T cells (2.5  x  106/animal) were inactivated by two rounds of freezing/thawing. 
II Animals were inoculated intravenously with  2.5  ￿  106 activated PPD-specific T cells. 
CD4+ BDV-specific  (NM 1) or PPD-specific (PPD) T cells were transferred after restimulation with the respective antigens and APCs on days + 3 
and  + 10 after BDV infection. 
using myelin basic protein-specific CD4 + T  cell lines to pro- 
tect rats against immunopathological experimental autoim- 
mune encephalomyelitis.  Here, viable as well as inactivated 
CD4 §  myelin basic protein-specific T  cells were shown to 
confer a protective immunity against passively or actively in- 
duced clinically manifest autoimmune encephalomyelitis in 
rats (23-26). Our data suggest that presence of a great number 
of viable antiviral effector cells at a time when relatively few 
brain cells were infected results in inhibition of virus spread 
and protection  against  clinical  disease.  This  means  that  in 
BDV infections of the CNS where lesions are potentially im- 
munopathological in character, the same cells that cause dis- 
ease can also prevent disease,  depending on the dynamics of 
the virus replication and the time of induction of the T  cell 
response. 
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